IPHA fundamentals
An in-depth look to Innate Pharma S.A. operating, investing, and financing activities
IPHA free cash flow for H2 23 is -22.87 M USD. For 2023, IPHA free cash flow was -35.58 M USD and operating cash flow was -35.2 M USD.
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: USD
TTM